High mobility group box 1 and kidney diseases (Review)
- Authors:
- Ping Zhu
- Li Xie
- Hua-Sheng Ding
- Quan Gong
- Jian Yang
- Lin Yang
-
Affiliations: Department of Nephrology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, P.R. China, Department of General Surgery, The First College of Clinical Medical Science, China Three Gorges University, Yichang, P.R. China, Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University, Yichang, P.R. China, Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, P.R. China - Published online on: February 25, 2013 https://doi.org/10.3892/ijmm.2013.1286
- Pages: 763-768
This article is mentioned in:
Abstract
 |
 |
|
Goodwin GH, Sanders C and Johns EW: A new group of chromatin-associated proteins with a high content of acidic and basic amino acids. Eur J Biochem. 38:14–19. 1973. View Article : Google Scholar : PubMed/NCBI | |
|
Bustin M, Lehn D and Landsman D: Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta. 1049:231–243. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Bonaldi T, Längst G, Strohner R, Becker PB and Bianchi ME: The DNA chaperone HMGB1 facilitates ACF/CHRAC-dependent nucleosome sliding. EMBO J. 21:6865–6873. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Travers AA: Priming the nucleosome: a role for HMGB proteins? EMBO Rep. 4:131–136. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Hock R, Furusawa T, Ueda T and Bustin M: HMG chromosomal proteins in development and disease. Trends Cell Biol. 17:72–79. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrari S, Finelli P, Rocchi M and Bianchi M: The active gene that encodes human high mobility group 1 protein (HMG1) contains introns and maps to chromosome 13. Genomics. 35:367–371. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kornblit B, Munthe-Fog L, Petersen S, Madsen H, Vindeløv L and Garred P: The genetic variation of the human HMGB1 gene. Tissue Antigens. 70:151–156. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Landsman D and Bustin M: A signature for the HMG-1 box DNA-binding proteins. Bioessays. 15:539–546. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Han J, Zhong J, Wei W, et al: Extracellular high-mobility group box 1 acts as an innate immune mediator to enhance autoimmune progression and diabetes onset in NOD mice. Diabetes. 57:2118–2127. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Dintilhac A and Bernués J: HMGB1 interacts with many apparently unrelated proteins by recognizing short amino acid sequences. J Biol Chem. 277:7021–7028. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Weir H, Kraulis P, Hill C, Raine A, Laue E and Thomas J: Structure of the HMG box motif in the B-domain of HMG1. EMBO J. 12:1311–1319. 1993.PubMed/NCBI | |
|
Messmer D, Yang H, Telusma G, et al: High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 173:307–313. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Ochani M, Li J, et al: Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA. 101:296–301. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Calogero S, Grassi F, Aguzzi A, et al: The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet. 22:276–280. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Müller S, Scaffidi P, Degryse B, et al: New EMBO member’s review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J. 20:4337–4340. 2001. | |
|
Ulloa L, Batliwalla FM, Andersson U, Gregersen PK and Tracey KJ: High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum. 48:876–881. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Brickman JM, Adam M and Ptashne M: Interactions between an HMG-1 protein and members of the Rel family. Proc Natl Acad Sci USA. 96:10679–10683. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Wang H, Bloom O, Zhang M, et al: HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:248–251. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Bianchi ME and Manfredi AA: High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 220:35–46. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Lamkanfi M, Sarkar A, Vande Walle L, et al: Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol. 185:4385–4392. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Svetkauskaite D, He Q, et al: Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 279:7370–7377. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Kokkola R, Andersson A, Mullins G, et al: RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 61:1–9. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hori O, Brett J, Slattery T, et al: The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J Biol Chem. 270:25752–25761. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Yang H, Wang H, Czura CJ and Tracey KJ: The cytokine activity of HMGB1. J Leukoc Biol. 78:1–8. 2005. View Article : Google Scholar | |
|
Merenmies J, Pihlaskari R, Laitinen J, Wartiovaara J and Rauvala H: 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J Biol Chem. 266:16722–16729. 1991. | |
|
Taguchi A, Blood DC, del Toro G, et al: Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 405:354–360. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Gamboni-Robertson F, He Q, et al: High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol. 290:C917–C924. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Park JS, Arcaroli J, Yum HK, et al: Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am J Physiol Cell Physiol. 284:C870–C879. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Yu M, Wang H, Ding A, et al: HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 26:174–179. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ivanov S, Dragoi AM, Wang X, et al: A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 110:1970–1981. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tian J, Avalos AM, Mao SY, et al: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. Nat Immunol. 8:487–496. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Oyama Y, Hashiguchi T, Taniguchi N, et al: High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest. 90:853–866. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Iwata Y, Furuichi K, Sakai N, et al: Dendritic cells contribute to autoimmune kidney injury in MRL-Faslpr mice. J Rheumatol. 36:306–314. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou JG, Dong JY, Zhang LH and Wang J: Expression of high mobility group box chromosomal protein 1 in mice with lupus nephritis. Zhejiang Da Xue Xue Bao Yi Xue Ban. 40:200–206. 2011.(In Chinese). | |
|
Pisetsky DS: HMGB1: a smoking gun in lupus nephritis? Arthritis Res Ther. 14:1122012. View Article : Google Scholar : PubMed/NCBI | |
|
Feng X, Hao J, Liu Q, et al: HMGB1 mediates IFN-γ-induced cell proliferation in MMC cells through regulation of cyclin D1/CDK4/p16 pathway. J Cell Biochem. 113:2009–2019. 2012. | |
|
Zickert A, Palmblad K, Sundelin B, et al: Renal expression and serum levels of high mobility group box 1 protein in lupus nephritis. Arthritis Res Ther. 14:R362012. View Article : Google Scholar : PubMed/NCBI | |
|
Bruchfeld A, Wendt M, Bratt J, et al: High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med. 17:29–35. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Sohn E, Kim CS, Jo K and Kim JS: The role of high-mobility group box-1 protein in the development of diabetic nephropathy. Am J Nephrol. 33:524–529. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lin M, Yiu WH, Wu HJ, et al: Toll-like receptor 4 promotes tubular inflammation in diabetic nephropathy. J Am Soc Nephrol. 23:86–102. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Penfold SA, Coughlan MT, Patel SK, et al: Circulating high-molecular-weight RAGE ligands activate pathways implicated in the development of diabetic nephropathy. Kidney Int. 78:287–295. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Torres VE, Harris PC and Pirson Y: Autosomal dominant polycystic kidney disease. Lancet. 369:1287–1301. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura T, Kawagoe Y, Ueda Y, Yamada S and Koide H: Hemoperfusion treatment in a septic shock patient with autosomal dominant polycystic kidney disease and increased HMGB1 protein levels. Blood Purif. 32:139–142. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura T, Sato E, Fujiwara N, et al: Changes in urinary albumin excretion, inflammatory and oxidative stress markers in ADPKD patients with hypertension. Am J Med Sci. 343:46–51. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Hu YM, Pai MH, Yeh CL, Hou YC and Yeh SL: Glutamine administration ameliorates sepsis-induced kidney injury by downregulating the high-mobility group box protein-1-mediated pathway in mice. Am J Physiol Renal Physiol. 302:F150–F158. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Q, Yao YM, Wang YB, et al: Effect of ethyl pyruvate on renal high mobility group box-1 protein expression and acute kidney injury in rats with delayed resuscitation after thermal injury. Zhonghua Wai Ke Za Zhi. 45:1210–1213. 2007.(In Chinese). | |
|
Chen J, Hartono JR, John R, et al: Early interleukin 6 production by leukocytes during ischemic acute kidney injury is regulated by TLR4. Kidney Int. 80:504–515. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chung KY, Park JJ and Kim YS: The role of high-mobility group box-1 in renal ischemia and reperfusion injury and the effect of ethyl pyruvate. Transplant Proc. 40:2136–2138. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wu H, Ma J, Wang P, et al: HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 21:1878–1890. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Li J, Gong Q, Zhong S, et al: Neutralization of the extracellular HMGB1 released by ischaemic damaged renal cells protects against renal ischaemia-reperfusion injury. Nephrol Dial Transplant. 26:469–478. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Bao YS, Na SP, Zhang P, et al: Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol. 32:587–594. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bruchfeld A, Qureshi AR, Lindholm B, et al: High mobility group box protein-1 correlates with renal function in chronic kidney disease (CKD). Mol Med. 14:109–115. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Sato F, Maruyama S, Hayashi H, et al: High mobility group box chromosomal protein 1 in patients with renal diseases. Nephron Clin Pract. 108:c194–c201. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Leelahavanichkul A, Huang Y, Hu X, et al: Chronic kidney disease worsens sepsis and sepsis-induced acute kidney injury by releasing high mobility group box protein-1. Kidney Int. 80:1198–1211. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Nakamura T, Sato E, Fujiwara N, et al: Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients. Metabolism. 58:1624–1628. 2009. View Article : Google Scholar | |
|
D’Agati V and Schmidt AM: RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol. 6:352–360. 2010. | |
|
Lynch J, Nolan S, Slattery C, Feighery R, Ryan MP and McMorrow T: High-mobility group box protein 1: a novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol. 32:590–602. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sandim V, Pereira D, Ornellas A and Alves G: Renal cell carcinoma and proteomics. Urol Int. 84:373–377. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lin L, Zhong K, Sun Z, Wu G and Ding G: Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma. J Cancer Res Clin Oncol. 13:11–22. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ganji MR and Harririan A: Chronic allograft dysfunction: major contributing factors. Iran J Kidney Dis. 6:88–93. 2012.PubMed/NCBI | |
|
Wang S, Schmaderer C, Kiss E, et al: Recipient Toll-like receptors contribute to chronic graft dysfunction by both MyD88- and TRIF-dependent signaling. Dis Model Mech. 3:92–103. 2010. View Article : Google Scholar : PubMed/NCBI |
